Dr. Maseras takes part in the meeting Perlas Retina 2017

Dr. Maseras takes part in the meeting Perlas Retina 2017

The 6th edition of the medical meeting Perlas Retina 2017 organized by Novartis and Alcon is held today, March 2nd in Madrid, and will gather renowned ophthalmologist from all over Spain.

Perlas Retina is an ophthalmology reference event that focuses on retinal diseases. From clinical cases, experiences related to surgical and medical management of these diseases are discussed and commented.

In Spain, an estimated 2 million people suffer from diseases that affect the retina. Some of these diseases are among the leading blindness causes in developed countries.

Nevertheless, the progress brought by new intraoperative visualization systems and developments in medical technology have substantially improved vitreoretinal surgery procedures.

Discussion topics

In this occasion, a series of complex clinical cases and complication that can arise both during and after the interventions will be presented. The aim is to make participants draw relevant conclusions on the topic with the expert help from panelists.

The discussion will also analyse how new technologies applied to surgical microscopes can be helpful during vitreoretinal surgeries.

Dr. Xavier Maseras, member of ICR Retina Department will take part as a panelist in the meeting, which will provide participants with a series of tools for everyday use in clinical practice.

Publica tu comentario

Tu dirección de correo no será publicada

ICR Ganduxer Headquarters

08022 Barcelona

ICR Pau Alcover

C. Pau Alcover 67
08017 Barcelona

ICR Terrassa

C. del Nord, 77
08221 Terrassa

Clínica Bonanova Surgical Center

Passeig Bonanova, 22
08022 Barcelona

Clinica Bonanova Tests and Treatments

c/ Mandri, 63
08022 Barcelona

ICR Service at Clínica Ntra. Sra. del Remei

c/ de l'Escorial,148
08024 Barcelona
This website uses cookies in order to collect statistical information regarding navigation. If you keep on surfing this website, it shall be deemed to have acknowledged its use. More information.